Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition

Testicular Germ Cell Tumors (TGCT) and patient-derived cell lines are extremely sensitive to cisplatin and other interstrand cross-link (ICL) inducing agents. Nevertheless, a subset of TGCTs are either innately resistant or acquire resistance to cisplatin during treatment. Understanding the mechanisms underlying TGCT sensitivity/resistance to cisplatin as well as the identification of novel strategies to target cisplatin-resistant TGCTs have major clinical implications. Herein, we have examined the proficiency of five embryonal carcinoma (EC) cell lines to repair cisplatin-induced ICLs. Using γH2AX staining as a marker of double strand break formation, we found that EC cell lines were either incapable of or had a reduced ability to repair ICL-induced damage. The defect correlated with reduced Homologous Recombination (HR) repair, as demonstrated by the reduction of RAD51 foci formation and by direct evaluation of HR efficiency using a GFP-reporter substrate. HR-defective tumors cells are known to be sensitive to the treatment with poly(ADP-ribose) polymerase (PARP) inhibitor. In line with this observation, we found that EC cell lines were also sensitive to PARP inhibitor monotherapy. The magnitude of sensitivity correlated with HR-repair reduced proficiency and with the expression levels and activity of PARP1 protein. In addition, we found that PARP inhibition strongly enhanced the response of the most resistant EC cells to cisplatin, by reducing their ability to overcome the damage. These results point to a reduced proficiency of HR repair as a source of sensitivity of ECs to ICL-inducing agents and PARP inhibitor monotherapy, and suggest that pharmacological inhibition of PARP can be exploited to target the stem cell component of the TGCTs (namely ECs) and to enhance the sensitivity of cisplatin-resistant TGCTs to standard treatments.

[1]  Haroon,et al.  A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes , 2022, Medicine.

[2]  中西 康詞.  Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication , 2012 .

[3]  T. Ludwig,et al.  BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. , 2012, Molecular cell.

[4]  A. Evans,et al.  PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy , 2011, Clinical Cancer Research.

[5]  M. Oren,et al.  p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin , 2011, PloS one.

[6]  S. de Jong,et al.  Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway , 2011, Cell Death and Disease.

[7]  Scott H. Kaufmann,et al.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.

[8]  A. Bürkle,et al.  How to Kill Tumor Cells with Inhibitors of Poly(adp-ribosyl)ation the Role of Poly(adp-rlbosyl)ation in Carcinogenesis , 2022 .

[9]  B. Kaina,et al.  Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression , 2010, Molecular Cancer.

[10]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[11]  S. Burma,et al.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. , 2010, Cancer research.

[12]  A. Shibata,et al.  Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair , 2010, Molecular Cancer Therapeutics.

[13]  M. Jasin,et al.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis , 2010, Nature Reviews Molecular Cell Biology.

[14]  Charles Giardina,et al.  DNA damage response to the Mdm2 inhibitor nutlin-3. , 2010, Biochemical pharmacology.

[15]  P. Glazer,et al.  Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 , 2010, Proceedings of the National Academy of Sciences.

[16]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[17]  S. Izraeli,et al.  A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors , 2009, Breast Cancer Research.

[18]  Katsuhiro Hanada,et al.  XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair , 2009, Molecular and Cellular Biology.

[19]  R. Dhir,et al.  Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. , 2009, Cancer research.

[20]  T. Helleday,et al.  The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links , 2009, Nucleic acids research.

[21]  N. Curtin,et al.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines , 2009, British Journal of Cancer.

[22]  Jingchuan Sun,et al.  Mechanism of Replication-Coupled DNA Interstrand Crosslink Repair , 2008, Cell.

[23]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[24]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Motzer,et al.  Medical treatment of advanced testicular cancer. , 2008, JAMA.

[26]  A. Clark.  The Stem Cell Identity of Testicular Cancer , 2007, Stem Cell Reviews.

[27]  C. Leonetti,et al.  Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. , 2007, European journal of cancer.

[28]  J. Hoeijmakers,et al.  First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. , 2007, American journal of human genetics.

[29]  Ying Liu,et al.  Qualification of Embryonal Carcinoma 2102Ep As a Reference for Human Embryonic Stem Cell Research , 2007, Stem cells.

[30]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[31]  Alan Horwich,et al.  Testicular germ-cell cancer , 2006, The Lancet.

[32]  Mariette Schrier,et al.  A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors , 2006, Cell.

[33]  Takeo Ohnishi,et al.  Does γH2AX foci formation depend on the presence of DNA double strand breaks , 2005 .

[34]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[35]  G. Viglietto,et al.  Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors , 2005, Oncogene.

[36]  Zhao-Qi Wang,et al.  Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Jeremy M. Stark,et al.  Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences , 2004, Molecular and Cellular Biology.

[38]  R. Day,et al.  Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines , 2004, International journal of cancer.

[39]  F. Lokiec,et al.  Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. , 2004, British journal of clinical pharmacology.

[40]  P. Brown,et al.  Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Masters,et al.  Curing metastatic cancer: lessons from testicular germ-cell tumours , 2003, Nature Reviews Cancer.

[42]  J. Richie.  Role of P53 and MDM2 in treatment response of human germ cell tumors. , 2003, The Journal of urology.

[43]  M. Grompe,et al.  DNA Replication Is Required To Elicit Cellular Responses to Psoralen-Induced DNA Interstrand Cross-Links , 2000, Molecular and Cellular Biology.

[44]  L. Thompson,et al.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. , 1999, Genes & development.

[45]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[46]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[47]  F. Mostofi,et al.  Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis , 1998, Cancer.

[48]  Y. Matsumura,et al.  Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. , 1998, Human molecular genetics.

[49]  A. Hall,et al.  Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. , 1996, European journal of cancer.

[50]  J. Moul,et al.  Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. , 1994, Cancer research.

[51]  I. Damjanov,et al.  Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[52]  M. Pera,et al.  Isolation and characterization of a multipotent clone of human embryonal carcinoma cells. , 1989, Differentiation; research in biological diversity.

[53]  T. Yagi,et al.  Establishment by SV40 transformation and characteristics of a cell line of xeroderma pigmentosum belonging to complementation group F. , 1983, Mutation research.

[54]  Craig R Moores,et al.  H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors , 1984, The Journal of experimental medicine.

[55]  P. Das,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[56]  Ricky A. Sharma,et al.  Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .

[57]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.

[58]  M. Jasin,et al.  Measuring recombination proficiency in mouse embryonic stem cells. , 2005, Methods in molecular biology.

[59]  Takeo Ohnishi,et al.  Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? , 2005, Cancer letters.

[60]  P. Andrews,et al.  Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7). , 1994, Laboratory investigation; a journal of technical methods and pathology.

[61]  H. Kienzer,et al.  Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.